Sesame, America’s Low-Cost Leader in Healthcare, Makes Compounded Semaglutide Available to Eligible Patients “At Cost,” with no Retail Price Markup
August 21, 2024 09:00 ET
|
Sesame
NEW YORK CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Sesame, the company that offers Americans quality, convenient health care at half the typical price, today announced the launch of “Success by...
MangoRx Completes Migration to DEA-Approved Telemedicine Platform, Accelerating Timeline of Oral Dissolvable GLP-1 Weight Loss Treatments Featuring Semaglutide and Tirzepatide
August 09, 2024 08:15 ET
|
Mangoceuticals, Inc.
Dallas, Texas, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health...
New Weight Loss Drugs Pose Anesthesia Risk, according to Journal of American Physicians and Surgeons
June 06, 2024 13:02 ET
|
Association of American Physicians and Surgeons
Weight loss drugs such as semaglutide impede stomach emptying, creating a significant risk from anesthesia. The effect may last for up to two months
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
May 01, 2024 09:00 ET
|
Elevai Labs Inc.
Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments
Wholesale Weight Loss: Sesame Unveils Specialized Care for Weight Loss with Pricing Exclusively for Costco Members
April 02, 2024 10:59 ET
|
Sesame
NEW YORK CITY, April 02, 2024 (GLOBE NEWSWIRE) -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, today unveiled an...
Non-Alcoholic Steatohepatitis Treatment Market revenue to reach USD 48.3 Billion by 2035, says Research Nester
March 06, 2024 06:00 ET
|
Research Nester
New York , March 06, 2024 (GLOBE NEWSWIRE) -- The global non-alcoholic steatohepatitis treatment market size is predicted to expand at 18% CAGR between 2023 and 2035. The market is projected to...
NATIONALLY RANKED ROSEN LAW FIRM Encourages Altimmune, Inc. Investors to Inquire About Securities Class Action Investigation – ALT
February 19, 2024 16:53 ET
|
The Rosen Law Firm PA
NEW YORK, Feb. 19, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Altimmune,...
Telehealth Evolution: Weightox Rx Enhances Access to Established Semaglutide Treatment for Modern Weight Loss
January 15, 2024 14:38 ET
|
Weightox Rx
Austin, Texas, Jan. 15, 2024 (GLOBE NEWSWIRE) -- In the evolving world of healthcare, telehealth solutions are significantly impacting how individuals access medical assistance, offering enhanced...
Polaris Group Announced the Acquisition of Genovior Biotech, Initiating Dual-Engine Growth
December 21, 2023 21:16 ET
|
Polaris Group
TAIPEI, Taiwan and SAN DIEGO, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550) announced that its board approved to increase the acquisition of Genovior Biotech's shares to...
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
November 28, 2023 08:00 ET
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...